Mesa Laboratories Management

Management criteria checks 3/4

Mesa Laboratories' CEO is Gary Owens, appointed in Sep 2017, has a tenure of 6.58 years. total yearly compensation is $5.19M, comprised of 14.1% salary and 85.9% bonuses, including company stock and options. directly owns 0.56% of the company’s shares, worth $3.06M. The average tenure of the management team and the board of directors is 6.6 years and 3.9 years respectively.

Key information

Gary Owens

Chief executive officer

US$5.2m

Total compensation

CEO salary percentage	14.1%
CEO tenure	6.6yrs
CEO ownership	0.6%
Management average tenure	6.6yrs
Board average tenure	3.9yrs

Recent management updates

Recent updates

Is Mesa Laboratories (NASDAQ:MLAB) Using Too Much Debt?

Mar 15

Mesa Laboratories, Inc. Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next

Feb 08

Investor Optimism Abounds Mesa Laboratories, Inc. (NASDAQ:MLAB) But Growth Is Lacking

May 31

A Look At The Intrinsic Value Of Mesa Laboratories, Inc. (NASDAQ:MLAB)

Apr 12

Does Mesa Laboratories (NASDAQ:MLAB) Have A Healthy Balance Sheet?

Mar 13

Estimating The Fair Value Of Mesa Laboratories, Inc. (NASDAQ:MLAB)

Dec 20

Mesa Laboratories declares $0.16 dividend

Oct 03

Mesa Laboratories: Softening Bottom Line Fundamentals, Fairly Priced

Sep 09

Are Investors Undervaluing Mesa Laboratories, Inc. (NASDAQ:MLAB) By 41%?

Sep 06

Does Mesa Laboratories (NASDAQ:MLAB) Have A Healthy Balance Sheet?

Aug 08

Mesa Laboratories GAAP EPS of -$0.27 misses by $0.27, revenue of $50.45M misses by $1.72M

Aug 04

Mesa Laboratories declares $0.16 dividend

Jul 07

A Look At The Intrinsic Value Of Mesa Laboratories, Inc. (NASDAQ:MLAB)

May 06

Growth Investors: Industry Analysts Just Upgraded Their Mesa Laboratories, Inc. (NASDAQ:MLAB) Revenue Forecasts By 14%

Apr 09

We Think Mesa Laboratories (NASDAQ:MLAB) Can Stay On Top Of Its Debt

Dec 08

CEO Compensation Analysis

How has Gary Owens's remuneration changed compared to Mesa Laboratories's earnings?
Date	Total Compensation	Salary	Company Earnings
Dec 31 2023	n/a	n/a	US$948k
Sep 30 2023	n/a	n/a	-US$717k
Jun 30 2023	n/a	n/a	US$2m
Mar 31 2023	US$5m	US$733k	US$930k
Dec 31 2022	n/a	n/a	-US$1m
Sep 30 2022	n/a	n/a	-US$4m
Jun 30 2022	n/a	n/a	-US$2m
Mar 31 2022	US$18m	US$579k	US$2m
Dec 31 2021	n/a	n/a	US$8m
Sep 30 2021	n/a	n/a	US$5m
Jun 30 2021	n/a	n/a	US$4m
Mar 31 2021	US$3m	US$524k	US$3m
Dec 31 2020	n/a	n/a	-US$2m
Sep 30 2020	n/a	n/a	-US$2m
Jun 30 2020	n/a	n/a	-US$2m
Mar 31 2020	US$3m	US$600k	US$2m
Dec 31 2019	n/a	n/a	US$5m
Sep 30 2019	n/a	n/a	US$10m
Jun 30 2019	n/a	n/a	US$8m
Mar 31 2019	US$3m	US$520k	US$7m
Dec 31 2018	n/a	n/a	US$10m
Sep 30 2018	n/a	n/a	-US$2m
Jun 30 2018	n/a	n/a	-US$249k
Mar 31 2018	US$1m	US$417k	-US$3m

Compensation vs Market: Gary's total compensation ($USD5.19M) is above average for companies of similar size in the US market ($USD2.37M).

Compensation vs Earnings: Gary's compensation has been consistent with company performance over the past year.

CEO

Gary Owens (55 yo)

6.6yrs

Tenure

US$5,190,371

Compensation

Mr. Gary M. Owens has been Chief Executive Officer, President and Director of Mesa Laboratories, Inc. since September 1, 2017. Mr. Owens joined as Chief Operating Officer in March 2017. Mr. Owens served as...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Gary Owens	CEO, President & Director	6.6yrs	US$5.19m	0.56% $ 3.1m
John Sakys	VP, CFO & Chief Accounting Officer	11.5yrs	US$1.91m	0.52% $ 2.8m
Brian Archbold	Senior Vice President of Continuous Improvement	6.3yrs	US$1.46m	0.010% $ 56.8k

6.6yrs

Average Tenure

54yo

Average Age

Experienced Management: MLAB's management team is seasoned and experienced (6.6 years average tenure).

Board Members

Name	Position	Tenure	Compensation	Ownership
Gary Owens	CEO, President & Director	6.6yrs	US$5.19m	0.56% $ 3.1m
Shiraz Ladiwala	Lead Independent Director	2.5yrs	US$217.55k	0.028% $ 152.7k
John Sullivan	Chairman of the Board	15.1yrs	US$255.10k	1.33% $ 7.3m
R. Tripeny	Independent Director	1.8yrs	US$219.97k	0.030% $ 163.4k
Mark Capone	Director	less than a year	no data	no data
Shannon Hall	Independent Director	3.9yrs	US$220.10k	0.032% $ 174.2k
Jennifer Alltoft	Independent Director	5.1yrs	US$210.10k	0.044% $ 244.3k

3.9yrs

Average Tenure

57yo

Average Age

Experienced Board: MLAB's board of directors are considered experienced (3.9 years average tenure).

Mesa Laboratories Management

Management criteria checks 3/4

Key information

Recent management updates

Mesa Laboratories, Inc. Appoints Mark Capone to Its Board of Directors

Insider notifies of intention to sell stock

CEO, President & Director notifies of intention to sell stock

Mesa Laboratories, Inc., Annual General Meeting, Aug 25, 2023

CEO, President & Director exercised options and sold US$166k worth of stock

Mesa Laboratories, Inc. Announces John B. Schmieder, Member of the Board of Directors, Chair of the Nominating and Governance Committee, and Member of the Audit Committee Decide Not to Stand for Re-Election

Recent updates

Third quarter dividend of US$0.16 announced

Mesa Laboratories, Inc. Declares Regular Quarterly Dividend, Payable on June 14, 2024

Mesa Laboratories, Inc. to Report Q4, 2024 Results on May 24, 2024

Is Mesa Laboratories (NASDAQ:MLAB) Using Too Much Debt?

Consensus EPS estimates upgraded to US$0.055 loss

Upcoming dividend of US$0.16 per share

Mesa Laboratories, Inc. Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next

New minor risk - Earnings quality

Third quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

Mesa Laboratories, Inc. Appoints Mark Capone to Its Board of Directors

Mesa Laboratories, Inc. Declares Regular Quarterly Dividend, Payable on March 15, 2024

Insider notifies of intention to sell stock

Mesa Laboratories, Inc. to Report Q3, 2024 Results on Feb 05, 2024

Is Mesa Laboratories, Inc. (NASDAQ:MLAB) Trading At A 43% Discount?

Upcoming dividend of US$0.16 per share at 0.7% yield

Price target decreased by 17% to US$115

Second quarter 2024 earnings: EPS and revenues miss analyst expectations

Mesa Laboratories, Inc. (NasdaqGS:MLAB) entered into a definitive agreement to acquire Beijing GKE Science & Technology Co. LTD for €5 million.

Mesa Laboratories, Inc. (NasdaqGS:MLAB) acquired Sterilization indicators business of GKE-GmbH and SAL GmbH from Gke-GmbH for €80 million.

Price target decreased by 8.9% to US$139

Mesa Laboratories, Inc. Declares Quarterly Dividend, Payable on December 15, 2023

Is Mesa Laboratories (NASDAQ:MLAB) A Risky Investment?

Mesa Laboratories, Inc. to Report Q2, 2024 Results on Nov 06, 2023

CEO, President & Director notifies of intention to sell stock

Upcoming dividend of US$0.16 per share at 0.5% yield

Estimating The Intrinsic Value Of Mesa Laboratories, Inc. (NASDAQ:MLAB)

First quarter 2024 earnings: EPS and revenues miss analyst expectations

New minor risk - Shareholder dilution

Mesa Laboratories, Inc., Annual General Meeting, Aug 25, 2023

We Think Mesa Laboratories (NASDAQ:MLAB) Is Taking Some Risk With Its Debt

Now 20% undervalued after recent price drop

Mesa Laboratories, Inc. to Report Q1, 2024 Results on Aug 03, 2023

CEO, President & Director exercised options and sold US$166k worth of stock

Consensus EPS estimates increase by 14%

Now 21% undervalued after recent price drop

Investor Optimism Abounds Mesa Laboratories, Inc. (NASDAQ:MLAB) But Growth Is Lacking

Price target decreased by 11% to US$178

Full year 2023 earnings: EPS and revenues miss analyst expectations

Upcoming dividend of US$0.16 per share at 0.4% yield

Mesa Laboratories, Inc. Announces John B. Schmieder, Member of the Board of Directors, Chair of the Nominating and Governance Committee, and Member of the Audit Committee Decide Not to Stand for Re-Election

A Look At The Intrinsic Value Of Mesa Laboratories, Inc. (NASDAQ:MLAB)

VP, CFO & Chief Accounting Officer notifies of intention to sell stock

Does Mesa Laboratories (NASDAQ:MLAB) Have A Healthy Balance Sheet?

VP, CFO & Chief Accounting Officer notifies of intention to sell stock

Upcoming dividend of US$0.16 per share at 0.4% yield

VP, CFO & Chief Accounting Officer exercised options and sold US$132k worth of stock

Third quarter 2023 earnings: EPS and revenues miss analyst expectations

VP, CFO & Chief Accounting Officer exercised options and sold US$293k worth of stock

Independent Director exercised options and sold US$137k worth of stock

Mesa Laboratories, Inc. Declares Quarterly Dividend, Payable on March 15, 2023

Estimating The Fair Value Of Mesa Laboratories, Inc. (NASDAQ:MLAB)

Mesa Laboratories, Inc. to Report Q3, 2023 Results on Feb 06, 2023

Upcoming dividend of US$0.16 per share

Now 21% undervalued after recent price drop

Mesa Laboratories, Inc. (NasdaqGS:MLAB) acquired Substantially all of the assets and certain liabilities from Belyntic GmbH.

Mesa Laboratories, Inc. Appoints Tony Tripeny as Member of Audit Committee

Second quarter 2023 earnings released: EPS: US$0.24 (vs US$0.71 in 2Q 2022)

Mesa Laboratories, Inc. Declares Quarterly Dividend, Payable on December 15, 2022

Mesa Laboratories declares $0.16 dividend

Mesa Laboratories: Softening Bottom Line Fundamentals, Fairly Priced

Are Investors Undervaluing Mesa Laboratories, Inc. (NASDAQ:MLAB) By 41%?

VP, CFO & Chief Accounting Officer exercised options and sold US$143k worth of stock

Upcoming dividend of US$0.16 per share

Independent Director recently sold US$198k worth of stock

VP, CFO & Chief Accounting Officer exercised options and sold US$260k worth of stock

Independent Director recently bought US$100k worth of stock

Does Mesa Laboratories (NASDAQ:MLAB) Have A Healthy Balance Sheet?

Now 21% undervalued after recent price drop

Mesa Laboratories GAAP EPS of -$0.27 misses by $0.27, revenue of $50.45M misses by $1.72M